Although controversial, HER2 overexpression has been observed more frequently in high tumor mutational burden and advanced T stage [86], while some studies evidenced a significant discordance between primary tumors and metastases, suggesting the loss of HER2 positivity during disease progression [94,95]. Here, ERBB2 is linked to neoplasm.